Prostate-Specific Antigen Level at Initiation of Hormonal Therapy After Prostate-Specific Antigen Failure Following Prostatectomy or Radiotherapy and Therapeutic Response

Urology

Volumn 70, Issue 2, 2007, Pages 320-323

  Alexander, Brian M ^a   Chen, Ming Hui ^b   Carroll, Peter ^c   D'Amico, Anthony V ^d  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 34548382678     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.074     Document Type: Article

References (13)

1. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
2. Zhou P., Chen M.H., McLeod D., et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992-6998
3. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
4. Stewart A.J., Scher H.I., Chen M.H., et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23 (2005) 6556-6560
5. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
6. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
7. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
8. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166 (2001) 500-507
9. Bianco Jr. F.J., Scardino P.T., Stephenson A.J., et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 448-453
10. Chung C.S., Chen M.H., Cullen J., et al. Time to prostate specific antigen (PSA) nadir following androgen suppression therapy for post-operative or post-radiation PSA failure and the risk of prostate cancer-specific mortality (2007) Presented at the Prostate Cancer Symposium, Orlando, Florida
11. D'Amico AV, McLeod DG, Carroll PR, et al: Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer (in press).
12. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
13. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512